Tag Archives: cancer

Oncology

Oncology Biosimilars: Opportunity or Not?

Posted on by John Santilli

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Continue reading →
Oncology

Big Data in Cancer Care: Limitations of Drug Claims

Posted on by John Santilli

Big Data in Cancer Care: Limitations of Drug Claims VBCC – March 2016, Vol 7, No 2 – Employers’ Perspective Catherine E. Cooke, PharmD, BCPS F. Randy Vogenberg, PhD, RPh Partner, National Institute of Collaborative Healthcare, and Access Market Intelligence; Principal, Institute for Integrated Healthcare Greenville, SC As one part of an ongoing macrotheme regarding big […]

Continue reading →
Trends

Impact of Commercial Insurance in 2017

Posted on by John Santilli
Clinical trial collaborations – an idea whose time has come
20
May

Impact of Commercial Insurance in 2017 – Considerable attention and planning has been focused on the Medicare market, but as we see from the chart below, Medicare represents approximately 13% of the total population.   Employer 49% Medicaid 19% Medicare 13% Uninsured 10% Non-Group 6% Other Public 2% (Source: Kaiser Family Foundation) A recent Mercer […]

Continue reading →
Dr. Randy Vogenberg

Oncology Care Marketing Increasing

Posted on by John Santilli
Knowsource.com Announces Transition to Access Market Intelligence
22
Apr

Oncology care marketing increasing in the U.S. marketplace. However, continuing benefit coverage planning for 2017 are also topics that are receiving increasing attention—to include cancer care. Just as the new oncology product pipeline is providing new options or treatments for a wide variety of cancers, market stakeholders are continuing to adjust their daily practices around providing […]

Continue reading →
Specialty Drug

Buy and Bill Trend: Are there Contradictions to Vendor or Pharma’s Reported Data

Posted on by John Santilli

Buy and Bill Trend:  Are there Contradictions to Vendor or Pharma’s Reported Data Distribution based sales of specialty pharmaceuticals raises critical issues for manufacturers and providers as plan year 2016 decisions have been made and 2017 preparations begin by purchasers. For pharmaceutical manufacturers, the dilemma arises when (1) reimbursement is limited or eliminated under benefit […]

Continue reading →
Market Intelligence

2015 Pharmaceutical Market Trend Vol. II

Posted on by John Santilli

Raising the Bar on performance So as to force companies to get lean, activist investors employ the use of shareholder arbitrage. There is increasing selection in licensing and partnering opportunities, and a reduced margin for error. Market-authorization for one-time results in periodic reevaluation throughout the life cycle of the product. There is relentlessness in the […]

Continue reading →
Distribution

Genentech Distribution Decision

Posted on by John Santilli

This is an example of a pharmaceutical company helping another group of healthcare stakeholders, health plans, because of an issue with health systems increasing cost of care. Stakeholders in the healthcare market, while working to reduce the cost of care, are trying to determine the best path to profitability. An example is Genentech’s decision to […]

Continue reading →
Market Intelligence

ACA is Limiting Patient Access to Cancer Centers

Posted on by Dr. Randy

Some of America’s best cancer hospitals are off-limits to many of the people now signing up for coverage under the nation’s new health care program, according to a recent story in the Washington Post. An Associated Press survey found examples coast to coast. Seattle Cancer Care Alliance is excluded by five out of eight insurers […]

Continue reading →